Overseeing Innovative Therapy without Mistaking it for Research: A Function-Based Model Based on Old Truths,New Capacities,and Lessons from Stem Cells

Fins J. F. , “Surgical Innovation and Ethical Dilemmas: Precautions and Proximity,” Cleveland Clinic Journal of Medicine 75, Supp. 6 (2008): S7–S12.

Curley M. A. Q. Hickey P. A. , “The Nightingale Metrics,” American Journal of Nursing 106, no. 10 (2006): 1–5.

The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, Ethical Principles and Guidelines for the Protection of Human Subjects of Research (Belmont Report), DHEW Publication OS78–0012, Washington, D.C., September 30, 1978.

Task Force for the Clinical Translation of Stem Cells, International Society for Stem Cell Research, Guidelines for the Clinical Translation of Stem Cells, Chicago, 2008.

Hyun I. , “Allowing Innovative Stem Cell-Based Therapies Outside of Clinical Trials: Ethical and Policy Challenges,” Journal of Law, Medicine & Ethics 38, no. 2 (2010).

National Cancer Institute, “Gene Therapy for Cancer Clinical Trials: Questions and Answers,” available at <http://www.cancer.gov/cancertopics/factsheet/Therapy/Gene> (last visited April 2, 2010)

Bamford K. B. Wood S. Shaw R. J. , “Standards for Gene Therapy Clinical Trials Based on Pro-active Risk Assessment in a London NHS Teaching Hospital Trust,” QJM 98, no. 2 (2005): 75–86.

Freedman B. , “Equipoise and the Ethics of Clinical Research,” New England Journal of Medicine 317, no. 3 (1987): 141–145; Beauchamp T. L. Childress J. F. , Principles of Biomedical Ethics (New York: Oxford University Press, 2001): at 322–323.

21 C.F.R. Parts 50, 56, 312, 314; 600, 812; 45 C.F.R. Part 46; International Conference on Harmonization (ICH) for Good Clinical Practice (GCP), July 2002, available at <http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf> (last visited April 2, 2010); World Medical Association Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects, revised October 2008, available at <http://ohsr.od.nih.gov/guidelines/helsinki.html> (last visited April 8, 2010).

Association for the Accreditation of Human Research Protection Programs, “Accreditation Standards and Principles,” available at <http://www.aahrpp.org/www.aspx?PageID=21> (last visited April 2, 2010); Wolf S. M. Lawrenz F. P. Nelson C. A. Kahn J. P. Cho M. K. Clayton E. W. Fletcher J. G. Georgieff M. K. Hammerschmidt D. Hudson K. Illes J. Kapur V. Keane M. A. Koenig B. A. LeRoy B. S. McFarland E. G. Paradise J. Parker L. S. Terry S. F. Van Ness B. Wilfond B. S. , “Managing Incidental Findings in Human Subject Research: Analysis and Recommendations,” Journal of Law, Medicine & Ethics 36, no. 2 (2008): 219–248.

Joint Commission on the Accreditation of Healthcare Organizations, “Accreditation Requirements,” revised 2009 as of March 26, 2009, available through <http://www.jointcommission.org/Standards/> (last visited April 2, 2010).

Robertson J. , “Legal Implications of the Boundaries between Biomedical Research involving Human Subjects and the Accepted or Routine Practice of Medicine,” December 31, 1975, in the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, Ethical Principles and Guidelines for the Protection of Human Subjects of Research (Belmont Report), at Appendix B, DHEW Publication OS78–0012, Washington, D.C., September 30, 1978.

Levine R. , “The Boundaries between Biomedical or Behavioral Research and the Accepted or Routine Practice of Medicine – Addendum,” September 25, 1975, in the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, Ethical Principles and Guidelines for the Protection of Human Subjects of Research (Belmont Report), Appendix A, Section 1, DHEW Publication OS78–0012, Washington, D.C., September 30, 1978.

Id., at 1–43.

Emanuel E. J. Wendler D. Grady C. , “What Makes Clinical Research Ethical?” JAMA 283, no. 2 (2000): 2701–2711.

Capron A. M. , “Containing Health Care Costs: Ethical and Legal Implications of Changes in the Methods of Paying Physicians,” Case Western Reserve Law Review 36, no. 4 (1986): 708–77; Fost N. , “Ethical Dilemmas in Medical Innovation,” Seminars in Perinatalogy 22, no. 3 (1998): 223–232.

Angell M. , “Medicine: The Endangered Patient-Centered Ethic,” Hastings Center Report 17, no. 1 (1987): S12–S13.

Pegram v. Herdrich , 530 U.S. 211 (2000).

Lo B. Wolf L. E. Berkeley A. , “Conflict-of-Interest Policies for Investigators in Clinical Trials,” New England Journal of Medicine 343, no. 22 (2000): 1616–1620; Angell M. , “Is Academic Medicine for Sale?” New England Journal of Medicine 342, no. 20 (2000): 1516–1518; DeAngelis C. D. Fontanarose P. B. , “Impugning the Integrity of Medical Science: The Adverse Effects of Industry Influence,” JAMA 299, no. 15 (2008): 1833–1835; Committee on Conflict of Interest in Medical Research, Education and Practice, Institute of Medicine, Conflict of Interest in Medical Research, Education and Practice (Washington, D.C.: National Academies Press. 2009).

Bayh-Dole Act, 35 U.S.C. 200–212, implementing regulations: 37 C.F.R. Part 401.

Armstrong D. , “Delicate Operation – How a Famed Hospital Invests In Device It Uses and Promotes. Cleveland Clinic Set Up Fund That Has Stock in Maker of Heart-Surgery System: Dr. Cosgrove's Multiple Roles,” Wall Street Journal, December 12, 2005, at A1.

Association for the Accreditation of Human Research Protection Programs, AAHRPP Accredits 67 Organizations in 2008; Up 42.6 Percent over Last Year, News Release, December 2008, available at <http://www.aahrpp.org/www.aspx?PageID=270> (last visited April 2, 2010).

Committee on Assessing the System for Protecting Human Research Participants of the Institute of Medicine of the National Academies of Medicine, Responsible Research: A Systems Approach to Protecting Research Participants (Washington, D.C.: National Academies Press, 2002).

Emanuel E. J. Wood A. Fleischman A. Bowen A. Getz K. A. Grady C. , “Oversight of Human Participants Research: Identifying Problems to Evaluate Reform Proposals,” Annals of Internal Medicine 141, no. 4 (2004): 282–291.

DeMets D.L. Fost N. Powers M. , “An Institutional Review Board Dilemma: Responsible for Safety Monitoring but Not in Control,” Clinical Trials 3, no. 2 (2006): 142–148.

Bankert E. Amdur R. , “The IRB Is Not a Data Safety Monitoring Board,” IRB: Ethics in Human Research 22, no. 6 (2000): 9–11.

Ladd R. E. , “Roles and Responsibilities of Ethics Committees,” American Journal of Bioethics 9, no. 4 (2009): 41–42.

Pearson S. D. Sabin J. E. Emanuel E. J. , No Margin, No Mission – Health Care Organizations and the Quest for Ethical Excellence (New York: Oxford University Press, 2003): At 25–44; Boyle P. J. DuBose E. R. Ellington S. J. Guinn D. E. McCurdy D. B. , Organizational Ethics in Health Care (San Francisco: John Wiley & Sons, Inc., 2001): At 23–28, 56–57, 73–74.

Committee on Guidelines for Human Embryonic Stem Cell Research, National Research Council, Institute of Medicine, Guidelines for Human Embryonic Stem Cell Research (Washington, D.C.: National Academies Press, 2005); Human Embryonic Stem Cell Research Task Force, International Society for Stem Cell Research, Guidelines for Human Embryonic Stem Cell Research, Chicago, 2006.

Committee on Quality of Health Care in America, Institute of Medicine, To Err Is Human (Washington, D.C.: National Academy Press, 2000); Committee on Quality of Health Care in America, Institute of Medicine, Crossing the Quality Chasm (Washington, D.C.: National Academy Press, 2001).

Committee on Quality of Health Care in America, Institute of Medicine, Crossing the Quality Chasm (Washington, D.C.: National Academy Press, 2001): at 76.

Lee T. H. Torchiana D. F. Lock J. E. , “Is Zero the Ideal Death Rate?” New England Journal of Medicine 357, no. 2 (2007): 111–113.

“Medicare Clinical Trial Policies – Overview,” available at <http://www.cms.hhs.gov/ClinicalTrialPolicies/> (last visited April 13, 2010); National Cancer Institute, “States that Require Health Plans to Cover Patient Care Costs in clinical Trials,” available at <http://www.cancer.gov/clinicaltrials/developments/laws-about-clinical-trial-costs> (last visited April 13, 2010).

McKinney's Consolidated Laws of New York, Insurance Law, Article 49, Title II; McKinney's Consolidated Laws of New York, Public Health Law, Article 49, Title II

45 C.F.R Part 46 (2009); 45 C.F.R 46.111 (“Criteria for IRB approval of research”).

See, e.g., Porter M.E. Teisberg E.O. , Redefining Health Care – Creating Value-Based Competition on Results (Boston: Harvard Business School Press, 2006).

Christensen C. M. Grossman J. H. Hwang J. , The Innovator's Prescription – A Disruptive Solution for Health Care (New York: McGraw Hill, 2009).